Skip to content
GLP-1 Desk
Menu
Dispatch #7Editorial

Effecty

Below-market pricing with brand access across all 50 states — a clean, no-frills value option.

Visit EffectyEditorial — no commercial relationship.
Semaglutide
$160/mo
Tirzepatide
$240/mo
Coverage
All 50 states
Brand-name
Yes

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency88/100
State access96/100
Molecule range90/100
Onboarding speed84/100
Support responsiveness82/100
Licensing & trust90/100

What the Desk likes

  • Low pricing on both molecules
  • Brand-name access available
  • Nationwide 50-state coverage

Where points come off

  • Injectable only — no oral route
  • Limited public track record

The Desk's briefing — B+

Best for: Patients who want affordable brand-capable care nationwide without extra program layers.

Effecty ranks #7 of 25 providers scored — see #1, CoreAge Rx on the board.

Related dispatches

Pricing and verification reflect Effecty's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Effecty's site. Not medical advice; see our disclosure.

← Back to The Desk